Cadila Pharmaceuticals Ltd., of Ahmedabad, India, and Altus Formulation Inc., of Montreal, signed a new co-development and licensing agreement covering Altus' Flexitab formulation platform. Under the terms of the agreement, the companies will jointly select key development targets benefiting from Flexitab, a validated tablet technology providing alcohol-resistant extended-release tablets that may be broken, with no change in performance, to generate bioequivalent lower-strength segments, and will co-develop and obtain marketing approval for those products in various territories. Products co-developed and commercialized under the agreement may be sublicensed to third parties around the globe.